Login
Companies $FULC
$3.72 +$0.01 (0.27%) After hours
Fulcrum Therapeutics, Inc. logo

Fulcrum Therapeutics, Inc.

fulcrumtx.com

What Do They Do?

Develops small-molecule drug candidates for people with genetically defined rare diseases, including pociredir for sickle cell disease.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▲ +44% (Loss)
vs −$19.6M in Q3 FY2025
  • Nov 12, 2026 Fulcrum agreed to sell early-stage fetal hemoglobin assets The sale is for approximately $7.0 million in cash and is contingent on completion of the proposed merger.
  • Aug 16, 2026 Fulcrum agreed to merge with Slate Medicines The combined company plans to focus on Slate’s migraine therapies and operate as Slate Medicines.
  • Jun 1, 2026 Fulcrum discontinued pociredir for sickle cell disease and began a strategic review The company cited FDA concerns about malignancy risk and said it saw no viable regulatory path for further clinical development.

Portfolio focus The older report described candidates for facioscapulohumeral muscular dystrophy and hemoglobin disorders; the latest centers on pociredir for sickle cell disease and says it will focus resources on core benign hematology programs.

Who Do They Compete With?

Competes with Bristol-Myers Squibb, Norgine, Novartis, Emmaus Life Sciences, Genetix Biotherapeutics, Vertex Pharmaceuticals, Pfizer, Novo Nordisk, GSK, Cellarity, Agios Pharmaceuticals, Sanofi, and Beam Therapeutics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support